Breast Cancer Biomarker Changes and Correlations with HER2 Change in ER Positive, HER2 Negative Breast Cancers Treated with Neoadjuvant Endocrine Therapy

被引：0
|
作者：
Huang, Wei [1 ]
Tyburski, Haley [2 ]
Finkelman, Brian [3 ]
Turner, Bradley [3 ]
Weiss, Anna [3 ]
Dhakal, Ajay [4 ]
Skinner, Kristin [3 ]
Hicks, David [3 ]
Zhang, Huina [3 ]
机构：
[1] Penn State Hlth Milton S Hershey Med Ctr, Hershey, PA USA
[2] Univ Rochester, Rochester, NY USA
[3] Univ Rochester, Med Ctr, Rochester, NY USA
[4] Univ Rochester, Med Ctr, Wilmot Canc Inst, Rochester, NY USA
来源：
LABORATORY INVESTIGATION | 2024年 / 104卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
146
引用
收藏
页码：S175 / S176
页数：2
相关论文
共 50 条
  • [1] Informative tools to optimize neoadjuvant therapy in ER positive, HER2 negative breast cancers.
    Luzhna, Lidiya
    Chia, Stephen
    Pauls, Mehrnoosh
    LeVasseur, Nathalie
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Predictive Biomarker of Response to Neoadjuvant Therapy in HER2 Positive Breast Cancer
    Zhao, Jing
    Meisel, Jane
    Suo, Aili
    Zhang, Chao
    Wei, Zhimin
    Aneja, Ritu
    Li, Zaibo
    Nahta, Rita
    Li, Xiaoxian
    [J]. LABORATORY INVESTIGATION, 2019, 99
  • [3] Role of endocrine therapy in ER+/HER2(+) breast cancers
    Webber, Victoria L.
    Dixon, J. Michael
    [J]. BREAST CANCER MANAGEMENT, 2014, 3 (01) : 103 - 111
  • [4] Comparison of metabolic changes between neoadjuvant chemotherapy and neoadjuvant endocrine therapy in premenopausal women with ER positive, HER2 negative breast cancer
    Ryu, H-H.
    Ahn, S. H.
    Son, B. H.
    Lee, J. W.
    Ko, B. S.
    Kim, J.
    Chung, I. Y.
    Kim, H.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [5] Comparison of metabolic changes after neoadjuvant endocrine and chemotherapy in ER positive, HER2 negative premenopausal women with breast cancer
    Ryu, Ho-Hyun
    Kim, Ji-Seon
    Chung, Il-Yong
    Lee, Jong-Won
    Ko, Beom-Seok
    Son, Byung-Ho
    Ahn, Sei-Hyun
    Kim, Hee-Jeong
    [J]. CANCER RESEARCH, 2020, 80 (04)
  • [6] The Genomic Landscape of ER Positive, HER2 Negative Breast Cancer
    Ramakrishna, M.
    Martin, S.
    Campbell, P. J.
    Futreal, P. A.
    Stratton, M. R.
    [J]. EUROPEAN JOURNAL OF CANCER, 2012, 48 : S132 - S132
  • [7] Evaluating the efficacy of neoadjuvant endocrine therapy in HER2 low vs. HER2 negative breast cancer: An NCBD analysis
    Chong, Esther G.
    Guo, Mengni
    Castillo, Dani Ran
    Bazan, Jose G.
    Yap, Kelly Khai Li
    Schultz-Costello, Katharine
    Wu, S. Peter
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Neoadjuvant therapy in patients with triple negative and HER2 positive early breast cancer
    Harbeck, N.
    [J]. BREAST, 2017, 32 : S18 - S18
  • [9] HER2 Immunohistochemistry Positivity is Strongly Predictive of HER2 Positive Breast Cancer Response to Neoadjuvant Therapy
    Zhao, Jing
    Zhang, Chao
    Suo, Aili
    Shi, Qiuying
    Wei, Zhimin
    Li, Zaibo
    Krishnamurti, Uma
    Li, Xiaoxian
    [J]. MODERN PATHOLOGY, 2019, 32
  • [10] HER2 Immunohistochemistry Positivity is Strongly Predictive of HER2 Positive Breast Cancer Response to Neoadjuvant Therapy
    Zhao, Jing
    Meisel, Jane
    Suo, Aili
    Zhang, Chao
    Wei, Zhimin
    Aneja, Ritu
    Li, Zaibo
    Nahta, Rita
    Li, Xiaoxian
    [J]. MODERN PATHOLOGY, 2019, 32
12345